Having trouble reading this newsletter? Click here to see it in your browser.
You are receiving this newsletter because you signed up from our web site. Click here to unsubscribe.
forward to a friend
10 May 2011
Current Partnering Newsletter

Dealmaker's News: May 2011

Sponsored by:
IBC: Biosimilars Asia 
Grand Hyatt Shanghai, China | 23-26 May, 2011
 
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the only conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
 
  • Discover latest legal challenges and patent expiries
  • What you need to  know about cost-effective clinical development
  • Explore game-changing moves, the “unholy alliances”, partnerships and collaborations
  • Equip yourself with the most recent global market outlook and pharmerging markets
  • Thought-provoking discussions featuring innovators, generics, biosimilars and industry thought-leaders
  • All you need to know about Biosimilarity, bioequivalence, substitutability, safety and patient acceptance concerns
  • Exclusive Pre & Post conference biosimilar development workshops and strategy briefing you won’t want to miss out
  • A must-attend for CSOs & Heads of R&D with well-researched topics
  • Opportunity to network with industry peers
 

To register for a place at this event, please visit the event website.


  • Editor's corner
  • In the news
  • Partnering reports
  • Forthcoming events
  • Scorecard update

Editor's corner

Hi,

After publishing our Companion Diagnostics Partnering Terms & Agreements report back in January and subsequently re-issuing this in April, this has now become our best-selling report of 2011. The report highlights the current relevance of the subject and companies' eagerness to learn more about the types of deals being negotiated in this area and under what terms these deals are being agreed upon.

Order now | more details | request sample pages

You may have seen our email message yesterday relating to Current Agreements - if you didn't, we have now made it possible to access the deals and alliances database for as little as 1 month! This is great news if you are perhaps a consultant working on a short-term project, or simply have a limited budget without the need for long-term access. Here are your options:

  • 1 month (from $1,000)
  • 3 month (from $2,000)
  • 6 month (from $3,000)
  • 12 month (from $5,000)
  • 24 month (from $8,000)

Subscribe now | request your free trial | more details

If you have any questions about any of our products relating to either Current Partnering or Current Agreements, please contact me and I'll be happy to help you.

 

Thanks and best wishes,

 

Claire.


In the news

Top deal-related news from the last few days:

 

Full details can be seen at Current Agreements.

Follow our news pages online at Current Partnering

View the latest breaking deals at Current Agreements

Request your free two-day trial of Current Agreements


Current Partnering report titles

Personalized Medicine Partnering Terms & Agreements
 
Pharmacogenomics Partnering Terms & Agreements
 
Partnering & M&A Agreements in Pharma & Biotech Yearbook: 2010
 
Companion Diagnostics Partnering Terms & Agreements - 2nd edition
 
Biomarker Partnering Terms and Agreements - 2nd edition
 
Partnering Terms and Agreements in Diagnostics, 2nd edition
 
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
 
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
 
Distribution Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
 
Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th edition
Buy now | order form | more details

Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 4th edition
Buy now | order form | more details

Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
 
Practical Guide to Finding Partners in Pharma & Biotech, 4th edition


Forthcoming Events

Here are some of our suggested events taking you through 2011:
 
EuroMedTech
Turin, Italy | 16-17 May, 2011 | More details
 
Euro-Biotech Forum
Paris, France | 23-25 May, 2011 | More details
 
C21 BioVentures
Napa CA, USA | 24-26 May, 2011 | More details
 
BIO International Convention
Washington DC, USA | 27-30 June 2011 | More details
 
Molecular Diagnostics for Cancer Drug Development
Boston MA, USA | 28-30 June 2011 | More details
 
WORLDx Congress
Baltimore MD, USA | 18-20 July, 2011 | More details
 
BioPharm America
Boston MA, USA | 7-9 September, 2011 | More details
 
BIO-Europe
Duesseldorf, Germany | 31 Oct - 2 Nov 2011 | More details
 
euroPLX 47
Geneva, Switzerland | 21-22 November, 2011 | More details
 


Scorecard update

Updated 10 May, 2011
 
Our Scorecard Index provides a simple overview of recent partnering and M&A activity - see it now - Scorecard Index.
 
In additon, we track the leading deals by value in the current year, plus a compendium of top deals by value since 2000 - view details at Scorecard.
 
Latest update! Bigpharma partnering activity 2006 to present - view details here 


Articles of the month

Alkermes buys up Elan Drug Delivery Technology Unit for $960m
10 May, 2011
Alkermes agreed to buy Elan drug Technologies, the drug delivery unit of Elan Corporation, in a deal valued at $960m. The deal will be funded by a $50 million cash payment... More
 
Teva outbids Valeant to acquire Cephalon
2 May, 2011
Cephalon has accepted a bid from Teva which values the company at $6.8 billion - some $1.1 billion more than the Valeant offer of several weeks ago. The accepted offer brings to an end what looked like... More

J&J nabs Synthes for $21.3 billion in biggest deal of the year to date
28 April, 2011
Johnson and Johnson have confirmed their acquisition of the Swiss medical company Synthes for $21.3 billion, following mounting speculation in recent weeks. More


Contact us!

Claire Nicholson, Editor

Web: http://www.CurrentPartnering.com

Mail: Wildwood Ventures Ltd., Eco Business Centre, Amy Johnson Way, Clifton Moor, York, YO30 4AG, United Kingdom

Tel: +44 1904 693200

Fax: +44 8703 305993

Email


Advertising and sponsorship

Current Partnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.

Or, contact us to discuss your requirements.


About Current Partnering

Current Partnering is an online provider of best practice, business information and intelligence for deal makers. We search out the latest information so you don’t have to and place it in one location, saving you precious time and resources.

 













































Current Partnering reports:

Current Partnering is a leading publisher of partnering business intelligence

Here is what our clients say about our reports:
 
"The information you provide is excellent and we look forward to doing more business with you in the future."
 
..."You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date..."
 
- for a full list of our latest publications visit the website at: www.currentpartnering.com





This email was sent to [email address suppressed]
Click here to instantly unsubscribe.

Current Partnering is a division of Wildwood Ventures Ltd
Wildwood Ventures Ltd is a registered company in the UK - number 5722617
Registered Office: Allanmere House, 6 Hobgate, York, YO24 4HF, United Kingdom
Email: enquiry@currentagreements.com